119th Congress
H.R. 9661
Expedited Access to Biosimilars Act
- Introduced
- In committee
- Passed House
- Passed Senate
- To President
- Became law
- Sponsor
- Nicholas A. Langworthy(R-NY)
- Introduced
- Jul 14, 2026
- Policy area
- Health
- Committees
- House Committee on Energy and Commerce
- Official text
- Introduced in House · Congress.gov page
Cosponsors (2)
Original cosponsors (1)
- Kim Schrier (D-WA)
Added later (1)
- Robert J. Wittman (R-VA) · Jul 21, 2026
Summary
No Congressional Research Service summary yet. CRS usually publishes one a few weeks after a bill is introduced.
Official title: To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.
Latest action(Jul 14, 2026): Referred to the House Committee on Energy and Commerce.
Roll-call votes
No recorded votes on this bill.
Actions
- Jul 14, 2026 · House
Referred to the House Committee on Energy and Commerce. - Jul 14, 2026
Introduced in House